• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » General Electric leads $100 million fund for breast cancer challenge

General Electric leads $100 million fund for breast cancer challenge

September 15, 2011
CenterWatch Staff

General Electric joined four venture capital firms in pledging $100 million for a six-month contest to finance ideas for improving breast cancer detection, according to Bloomberg.

The goal is to speed the diagnosis of breast cancer, the most common form of the disease in women, and find more-precise therapies, GE said. Breast cancer also will be the initial focus of a $1 billion GE investment over five years to develop products to detect disease early and treat tumors.

“In the case of breast cancer, there’s some meaningful therapies, it’s such a pervasive disease, we thought it was a good place to start,” said Immelt. “There’s a chance for this disease to go chronic in some cases.”

The contest is modeled on a smartgrid drive under GE’s ecomagination initiative, which includes a $200 million fund that has put up financing for 22 small companies and entrepreneurs working on so-called renewable technologies. The $1 billion is part of the $6 billion GE pledged to spend under its Healthymagination campaign begun two years ago.

The contest will use both direct investments and grant access to the Fairfield, Connecticut-based company’s sales force and research and development resources, also awarding $100,000 for universities for research.

Immelt has been building out the health-care business at GE, expanding partnerships and boosting research with an eye toward making cancer diagnosis more precise.

GE will contribute half of the $100 million fund. Venture capital firms Kleiner Perkins Caufield & Byers, Venrock Associates, Mohr Davidow Ventures and MPM Capital will provide the rest. Immelt and executives from the firms said the initiative is a chance for GE to offer small companies funding at a time when investment opportunities are scarce.

The cancer initiative also includes a three-year partnership with Susan G. Komen for the Cure, a non-profit group that raises money for breast cancer research, to expand women’s access to new technologies to fight the disease, GE said. Initial programs will be in Wyoming, Saudi Arabia and China.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing